Abstract:Chronic myeloid leukemia (CML) is characterized by the accumulation of malignant and immature white blood cells which spread to the peripheral blood and other tissues/organs. Despite the fact that current tyrosine kinase inhibitors (TKIs) are capable of achieving the complete remission by reducing the tumor burden, severe adverse effects often occur in CML patients treated with TKIs. The differentiation therapy exhibits therapeutic potential to improve cure rates in leukemia, as evidenced by the striking success of all-trans-retinoic acid in acute promyelocytic leukemia treatment. However, there is still a lack of efficient differentiation therapy strategy in CML. Here we showed that MPL, which encodes the thrombopoietin receptor driving the development of hematopoietic stem/progenitor cells, decreased along with the progression of CML. We first elucidated that MPL signaling blockade impeded the megakaryocytic differentiation and contributed to the progression of CML. While allogeneic human umbilical cord-derived mesenchymal stem cells (UC-MSCs) treatment efficiently promoted megakaryocytic lineage differentiation of CML cells through restoring the MPL expression and activating MPL signaling. UC-MSCs in combination with eltrombopag, a non-peptide MPL agonist, further activated JAK/STAT and MAPK signaling pathways through MPL and exerted a synergetic effect on enhancing CML cell differentiation. The established combinational treatment not only markedly reduced the CML burden but also significantly eliminated CML cells in a xenograft CML model. We provided a new molecular insight of thrombopoietin (TPO) and MPL signaling in MSCs-mediated megakaryocytic differentiation of CML cells. Furthermore, a novel anti-CML treatment regimen that uses the combination of UC-MSCs and eltrombopag shows therapeutic potential to overcome the differentiation blockade in CML.

Expression of MPL in Leukemia Stem Cells and Its Role in Stemness Maintainance

C-Mpl is a Candidate Surface Marker and Confers Self-Renewal, Quiescence, Chemotherapy Resistance, and Leukemia Initiation Potential in Leukemia Stem Cells

Leukemia Stem Cells: the Root of Chronic Myeloid Leukemia

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells

[Expression of C-Mpl in Leukemic Stem Cells from Acute Myeloid Leukemia Patients].

Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute myeloid leukemia stem cells

Regulation of Malignant Myeloid Leukemia by Mesenchymal Stem Cells

Deciphering the differential impact of thrombopoietin/MPL signaling on hematopoietic stem/progenitor cell function in bone marrow and spleen

Dynamic Localization of Leukemia Stem Cells via CXCL12 Regulates Leukemia Progression

Establishment of a Novel Mesenchymal Stem Cell-Based Regimen for Chronic Myeloid Leukemia Differentiation Therapy

The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting

OPN Maintains Leukemia Stem Cells Survival by Suppressing PUMA

Transposable Elements Shape Stemness in Normal and Leukemic Hematopoiesis

CX43-mediated mitochondrial transfer maintains stemness of KG-1a leukemia stem cells through metabolic remodeling

Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development

A review on the functional characteristics of the c-Myeloproliferative Leukaemia (c-MPL) gene and its isoforms

PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway

Epigenetic mechanisms controlling human leukemia stem cells and therapy resistance

Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway

Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia